by Raynovich Rod | Apr 4, 2013 | 2024 Rayno Biopharmaceuticals Portfolio, BIOgraph, Macro
Biotechnology Sector Q2 2013- At All Time Highs The BTK and ETFs such as the IBB and XBI hit all time highs on April 2. Of course the current ramp cannot go on forever because money moves on, speculation ebbs and math intervenes. We have been picking biotech stocks...
by Raynovich Rod | Apr 3, 2013 | BIOgraph, Macro
Pause in Rally as Large Cap Biotechs Are Weak There is significant weakness today in many high fliers that is not apparent in the S&P, NASDAQ and Russell averages. The IBB hit a new high yesterday at the $162 level and is off 1% today. Large Cap leaders YTD are...
by Raynovich Rod | Mar 22, 2013 | BIOgraph, Biopharmaceuticals
Rayno Biopharmaceutical Stocks In a Stealth Rally-Most Core Positions Up No changes have been made in core portfolio positions except as noted below. See update in Seeking Alpha. Action today with strong charts since Feb 26 Sell-Off ALXN ($93) stable and recovering...
by Raynovich Rod | Mar 6, 2013 | 2024 Rayno Tools and Diagnostics Portfolio, BIOgraph
Sector Drivers include Technology Innovation and M&A The Life Science Tools and Diagnostics sector is important for diversification of any biotechnology portfolio.The stocks are less volatile than biopharmaceuticals and less driven by momentum players because the...
by Raynovich Rod | Mar 4, 2013 | BIOgraph, Biopharmaceuticals
Biotech Rally Takes Sector to New Highs After a brief lull many biopharmaceuticals stocks are rallying over 2% today. Recently we reiterated Cubist (CBST $45.38) up 4.4% and Optimer (OPTR $12.62) up 3.34% and both are among big movers today. Taking the lead from some...
by Raynovich Rod | Feb 28, 2013 | BIOgraph
Market Reverses Late in the Day Giving Pause to Euphoria Intuitive Surgical (ISRG $509.89) plunged 11% in final minutes upon disclosure from Bloomberg of a safety probe from U.S. regulators. An FDA survey is trying to determine “whether adverse incident reports...
by Raynovich Rod | Feb 26, 2013 | 2024 Rayno Biopharmaceuticals Portfolio, BIOgraph
Caution-Follow Technicals-Potential for Macro Risk Off The Life Science sector is about 2% off highs of February 1 and has formed a double top from October 5 highs. In recent posts we urged caution as some MO stocks had blow-off tops (ALXN,MDVN, REGN) and the IBB and...
by Raynovich Rod | Feb 26, 2013 | 2024 Rayno Tools and Diagnostics Portfolio, BIOgraph
Genomic Health-Good Long Term Value This looks like a good entry point for buying shares of Genomic Health (GHDX $28.50), a molecular diagnostic company focused on personalized medicine for cancer with its oncotype DX invasive breast cancer test.Yesterday the Company...
by Raynovich Rod | Feb 22, 2013 | BIOgraph, Biopharmaceuticals
Technicals Still Rule As Momentum Eases-Reiterate Caution MO favs down: INFI, MDVN, PCYC The Life Science sector is up about 1% after two days of selling on heavy volume. The bellwether ETFs (IBB $145.16) are about 2% off 52 week highs and we do not expect this...
by Raynovich Rod | Feb 19, 2013 | BIOgraph, Biopharmaceuticals
The BIG money in biotech has moved on to new names like Infinity (INFI) up 15 points since December. In the meantime they are moving out of the big winners from 2012 like Alexion (ALXN $83.4) down 3% and Regeneron (REGN $160) down 2.7% . See previous postings. The...
